Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 15/20 | 0.63 |
| ▸ | BRD4 | O60885 | 9/20 | 0.63 |
| ▸ | BRDT | Q58F21 | 7/20 | 0.63 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.55 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.55 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.52 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | PRKCG | P05129 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.51 |
| ▸ | NEK4 | P51957 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.51 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.51 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.51 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675572 | 0.97 | PLK1 (0.62) | PLK1BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL1675750 | 0.95 | PLK1 (0.65) | PLK1BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL1675993 | 0.94 | PLK1 (0.63) | PLK1BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL4109431 | 0.93 | BRD4 (0.56) | PLK1BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL1559323 | 0.93 | PLK1 (0.66) | PLK1BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL1675856 | 0.92 | PLK1 (0.69) | PLK1BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL4303951 | 0.90 | PLK1 (0.57) | PLK1BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL4113504 | 0.90 | PLK1 (0.57) | PLK1BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL4126462 | 0.90 | PLK1 (0.57) | PLK1BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL4117341 | 0.90 | PLK1 (0.57) | PLK1BRD4BRDTDCLK1MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2564850-B1 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | claimed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | claimed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | claimed |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | US | claimed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | claimed |
| EP-2564850-B1 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-8318727-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8026234-B2 | Polo-like kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281092-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | PLK1 1/4885BRD4 1323/4885BRDT 579/4885 |
| US-20110201818-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | PLK1 1/4885BRD4 1323/4885BRDT 579/4885 |
| US-20110082111-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | PLK1 1/4885BRD4 1323/4885BRDT 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.